Ocugen is trading 10.13% down at $0.80, with no clear company-specific news explaining the decline.
- Today’s OCU400 licensing announcement covers exclusive MENA rights and potential milestone payments, but does not establish a reason for the drop.
- Hotter-than-expected U.S. inflation lifted rate-hike expectations and pressured major indexes; the biotech sector is also lower.
- These broader market conditions provide context, not proof of the precise cause of Ocugen’s decline.